African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women

J Clin Oncol. 2009 Aug 1;27(22):e35-7; author reply e38-9. doi: 10.1200/JCO.2008.21.5509. Epub 2009 Jun 29.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Anthracyclines / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Black or African American / statistics & numerical data*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / ethnology*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / mortality
  • Breast Neoplasms / pathology
  • Bridged-Ring Compounds / administration & dosage
  • Cohort Studies
  • Disease-Free Survival
  • Female
  • Humans
  • Mastectomy, Segmental / methods
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Receptor, ErbB-2 / metabolism
  • Receptors, Estrogen / analysis*
  • Receptors, Estrogen / metabolism
  • Receptors, Progesterone / metabolism
  • Registries
  • Risk Assessment
  • Survival Analysis
  • Taxoids / administration & dosage
  • Treatment Outcome
  • White People / statistics & numerical data*

Substances

  • Anthracyclines
  • Bridged-Ring Compounds
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Taxoids
  • taxane
  • Receptor, ErbB-2